Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
News|Articles|January 20, 2026
State of the Bio/Pharma Workforce: A Comparative Analysis of Employment Trends and Industry Sentiment
Author(s)Christopher Cole
A comparison of 2024 and 2025 bio/pharma employment survey results indicates that industry professionals face eroding security, polarized satisfaction, and rising attrition risk.
This article was originally published by
Related to this article
TRexBio and Retension Pharmaceuticals priced IPOs, raising a combined $161.7 million to advance their immunology and hypertension pipelines ahead of their Nasdaq debuts.
Viatris is acquiring Pacira BioSciences for $1.65 billion in cash, adding non-opioid pain therapies Exparel and Zilretta.
Ultragenyx is selling it's Rare Pediatric Disease Priority Review Voucher earned for Genglycos’s approval for $210 million.
Why hub vendor transitions fail — and the four questions every manufacturer should answer before signing with a new patient support program vendor.
A passing FDA inspection tells pharma senior leadership very little about whether the next significant revenue vulnerability is already taking shape. But continuous, AI-enabled quality management maturity (QMM) has the potential to do so months before the issue reaches the realm of P&L.
Caribou Biosciences is discontinuing its two allogeneic CAR-T programs and exploring strategic alternatives to maximize shareholder value.
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.